• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Routine cerebral embolic protection in transcatheter aortic valve implantation: rationale and design of the randomised British Heart Foundation PROTECT-TAVI trial
EuroIntervention. 2023 Jan 26:EIJ-D-22-00713. doi: 10.4244/EIJ-D-22-00713. Online ahead of print.ABSTRACTTranscatheter aortic valve implantation (TAVI) is an established treatment for aortic stenosis. Cerebral embolic protection (CEP) devices may impact periprocedural stroke by capturing debris destined for the brain. However, there is a lack of high-quality randomised trial evidence supporting the use of CEP during TAVI. The British Heart Foundation (BHF) PROTECT-TAVI trial will address whether the routine use of CEP reduces the incidence of stroke in patients undergoing TAVI. BHF PROTECT-TAVI is a prospective, open-label...
Source: EuroIntervention - January 27, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Rajesh K Kharbanda Alexander David Perkins James Kennedy Adrian P Banning Andreas Baumbach Daniel J Blackman Matthew Dodd Richard Evans David Hildick-Smith Zahra Jamal Peter Ludman Stephen Palmer Rodney Stables Tim Clayton Source Type: research

Transcatheter Aortic Valve Replacement Versus Aortic Valve Bypass
Conclusions TAVR and AVB relieve aortic stenosis and have similar and acceptable procedural mortality rates. AVB-treated patients had 1.75 times the STS risk score when compared with the TAVR cohort. Hospital charges for TAVR were nearly twofold those of AVB. Hospital reimbursement was similar, but AVB had two to four times the profit margin of TAVR. Longer follow-up for the TAVR cohort will determine whether survival is comparable to that after AVB at 3 and 5 years.
Source: The Annals of Thoracic Surgery - September 12, 2015 Category: Cardiovascular & Thoracic Surgery Source Type: research

Transcatheter Aortic Valve Replacement Versus Aortic Valve Bypass: A Comparison of Outcomes and Economics.
CONCLUSIONS: TAVR and AVB relieve aortic stenosis and have similar and acceptable procedural mortality rates. AVB-treated patients had 1.75 times the STS risk score when compared with the TAVR cohort. Hospital charges for TAVR were nearly twofold those of AVB. Hospital reimbursement was similar, but AVB had two to four times the profit margin of TAVR. Longer follow-up for the TAVR cohort will determine whether survival is comparable to that after AVB at 3 and 5 years. PMID: 26365675 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - September 11, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Brown JW, Boyd JH, Patel PM, Baker ML, Syed A, Ladowski J, Corvera J Tags: Ann Thorac Surg Source Type: research

Cost‐effectiveness of percutaneous coronary intervention with drug‐eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery 5 years after intervention
Conclusions. Cost‐effectiveness analysis of DES‐PCI vs. CABG demonstrated that CABG is the most effective, but most costly, treatment for preventing MACCE in patients with multivessel disease. © 2013 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - January 9, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Lisa Krenn, Christoph Kopp, Dietmar Glogar, Irene M Lang, Georg Delle‐Karth, Thomas Neunteufl, Gerhard Kreiner, Alexandra Kaider, Jutta Bergler‐Klein, Aliasghar Khorsand, Maryam Nikfardjam, Günther Laufer, Gerald Maurer, Mariann Gyöngyösi Tags: Research Article Source Type: research